# Phase II Study Comparing Conversion Rate to Surgery With Hepatic Arterial Infusion Chemotherapy to Systemic Chemotherapy in Patients With Non Resectable Liver-only Colorectal Metastases

> **NCT05103020** · PHASE2 · UNKNOWN · sponsor: **Yonsei University** · enrollment: 100 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** intra-arterial oxaliplatin + Systemic FOLFIRI + target agent (bevacizumab or cetuximab) every 2 weeks
- **DRUG:** IV FOLFIRI+ target agent (bevacizumab or cetuximab) every 2 weeks

## Key facts

- **NCT ID:** NCT05103020
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-11-01
- **Primary completion:** 2023-03
- **Final completion:** 2025-03
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2021-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05103020

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05103020, "Phase II Study Comparing Conversion Rate to Surgery With Hepatic Arterial Infusion Chemotherapy to Systemic Chemotherapy in Patients With Non Resectable Liver-only Colorectal Metastases". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT05103020. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*